New Online Poll Reveals Support for Host Response Testing in Antibiotic Stewardship Among Healthcare Professionals and Patient Advocates

73% of respondents agree that host response testing helps guide antibiotic stewardship efforts

SEATTLE and BRISBANE, Australia, June 10, 2025 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the results from an online poll conducted during the Sepsis Alliance AMR Conference on April 30, 2025.

An online poll of healthcare professionals engaged in sepsis programs and patient advocates shed light on critical perspectives in healthcare regarding antibiotic stewardship as well as the diagnosis and treatment of sepsis. The results indicated that 73% of the 236 respondents believed host response testing can help guide antibiotic stewardship efforts, emphasizing the potential of tools based on this approach to optimize antibiotic use and combat antimicrobial resistance.

"As antimicrobial resistance intensifies, the risk of infections progressing to sepsis rises, leading to more challenging cases and adverse outcomes like amputations and fatalities," stated Tom Heymann, President and CEO of Sepsis Alliance. "Collaborative efforts across sectors, ongoing innovation, and educational initiatives are essential to manage this intricate clinical interplay and tackle the global threat of antimicrobial resistance."

Additionally, the online poll revealed concerns about sepsis treatment practices, with 43% of the 101 poll respondents reporting that they think their patients are overtreated, while 28% noted undertreatment. These findings underscore the need for more precise diagnostic tools and treatment strategies to address the complexities of sepsis care.

"We are gratified by the support from the clinical community for host response testing in the diagnosis and treatment of sepsis," said Rollie Carlson, CEO of Immunexpress. "In particular, the fact that 69 respondents specifically indicated that they would advocate for the use of a host response diagnostic tool like SeptiCyte® RAPID in their own organization is a clear indicator of the need for better diagnostic tools in sepsis and to combat antimicrobial resistance."

About Sepsis Alliance

Sepsis Alliance, a leading patient advocacy organization, is saving lives and reducing suffering by improving sepsis awareness and care. Through Sepsis.org, Sepsis Alliance Institute, Sepsis Alliance Voices, and Sepsis Alliance Connect, Sepsis Alliance is providing healthcare professionals, the general public, and those touched by sepsis with the education, support, and advocacy to save lives and limbs. Sepsis Alliance is enacting and influencing positive change for the 1.7 million people diagnosed with sepsis each year including the 350,000 adults and 6,800 children who die in the U.S. Infection prevention is sepsis prevention™. For more information on Sepsis Alliance, a GuideStar Platinum Rated and Charity Navigator Four-Star rated 501(c)3 charity, visit Sepsis.org.

About SeptiCyte® RAPID

SeptiCyte® RAPID is a sample-to-answer, cartridge-based, host response molecular test for sepsis using reverse transcription polymerase chain reaction (RT-PCR) to quantify the relative expression levels of host response genes isolated from whole blood. SeptiCyte® RAPID is used in conjunction with clinical assessments, vital signs and laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation response syndromes in patients with escalating signs and symptoms of critical illness. SeptiCyte® RAPID generates a score (SeptiScore®) that falls within four discrete interpretation bands based on the increasing likelihood of sepsis. SeptiCyte® RAPID is intended for in-vitro diagnostic use and runs on the Biocartis Idylla™ Platform.

SeptiCyte® RAPID is CE Marked as a near-patient sample-to-answer test in European Union (EU) member countries and those harmonized with the EU IVD Directive (98/79/EC). As of November 2021, SeptiCyte® RAPID has been FDA cleared for use in hospitalized patients suspected of sepsis.

About Immunexpress

Immunexpress is a molecular diagnostic company, based in Brisbane and Seattle, committed to improving outcomes for patients suspected of sepsis. Immunexpress' SeptiCyte® technology can assess a patient's dysregulated immune response by quantifying and analyzing gene expression from whole blood, providing actionable results in about an hour from sepsis suspicion, to guide the physician in optimizing patient management decisions. SeptiCyte® RAPID is a lab test for sepsis that combines SeptiCyte® technology with the ease-of-use of the revolutionary Biocartis' Idylla™ Platform; it supports differentiating infection (bacterial, viral, fungal) positive sepsis that could lead to organ dysfunction and death from patients with less serious infection negative systemic inflammation. This powerful test enhances early sepsis detection and can strongly support its diagnosis in the crucial first hour(s) that determines clinical outcome. SeptiCyte® RAPID also has a high potential to reduce sepsis associated healthcare costs.

For more information, visit and https://immunexpress.com. Follow Immunexpress on Twitter and LinkedIn. 

Immunexpress Media Contacts:  

David Schull
Russo Partners, LLC
[email protected]

Maddie Stabinski 
Russo Partners, LLC  
[email protected]  

SOURCE Immunexpress, Inc.